<DOC>
	<DOCNO>NCT02467335</DOCNO>
	<brief_summary>A single oral dose study subject hepatic impairment healthy control subject . Subjects stay clinical facility interval blood sampling obtain examined drug effect .</brief_summary>
	<brief_title>Single-dose Pharmacokinetics BMS-626529 , Administered BMS-663068 , Subjects With Hepatic Impairment Compared Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Males female , age 18 70 year , inclusive BMI : 18.5 38 kg/m2 Body weight great equal 45.5 kg Subjects hepatic impairment Subjects hepatic impairment must stable dose medication and/or treatment regimen Healthy subject extent possible match first four subject hepatic impairment regard age , body weight , sex , determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Any major surgery within 4 week study drug administration Donation blood blood bank clinical study ( except screen visit ) within 4 week study drug administration ( within 2 week plasma ) Subject require additional medication hepatic encephalopathy within 12 month ( 6 month severe hepatic impairment ) prior dose Presence severe ascites edema subject , judge PI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>